Hosted on MSN16d
FDA CDER director Patrizia Cavazzoni announces resignation
Following a string of FDA resignations, Patrizia Cavazzoni has announced that her last day will be 18 January.
Patrizia Cavazzoni, key FDA official, to leave agency
The director of the FDA's main drug review office will exit on Jan. 18, according to an email sent to staff. Her departure is one of several announced by high-ranking FDA leaders ahead of the coming ...
Investor's Business Daily on MSN9d
Here's How Donald Trump Could Shake Up Health Care — And Biotech Stocks
Biotech stocks have slumped 15% since Donald Trump won his second presidency. That's because Trump comes with a lot of ...
Becker's Hospital Review17d
FDA drug evaluation leader to exit
The director of the FDA's Center for Drug Evaluation and Research, Patrizia Cavazzoni, MD, will step down from the role Jan. 18, according to an Endpoints News report. Dr. Cavazzoni joined the FDA ...
HHS Secretary Becerra urges Trump administration to 'continue to grow' the ACA
As of Monday, FDA commissioner Robert Califf, Department of Health and Human Services (HHS) Secretary Xavier Becerra, ...
pharmaphorum5d
FDA launches innovation hub to spur rare disease R&D
It will be co-led by Patrizia Cavazzoni, director of the FDA's Centre for Drugs Evaluation and Research (CDER), and Centre for Biologics Evaluation and Research (CBER) director Peter Marks.
AOL1mon
Off-brand versions of Lilly weight loss drug must be pulled off market, could mean higher prices
Patrizia Cavazzoni, the director of the FDA’s Center for Drug Evaluation and Research, said in a letter last week that the demand for Zepbound and Mounjaro is being met, negating the need for ...
JPM25: The FDA’s future, AbbVie’s second thoughts and Lilly’s lesson
AbbVie's CEO hinted his company may be less willing to invest in psychiatry, while Lilly explained what it got wrong forecasting GLP-1 drug demand.